These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Inhalable nanoparticulate powders for respiratory delivery. Muralidharan P; Malapit M; Mallory E; Hayes D; Mansour HM Nanomedicine; 2015 Jul; 11(5):1189-99. PubMed ID: 25659645 [TBL] [Abstract][Full Text] [Related]
26. Pulmonary Delivery of Emerging Antibacterials for Bacterial Lung Infections Treatment. Li J; Zheng H; Leung SSY Pharm Res; 2023 May; 40(5):1057-1072. PubMed ID: 36123511 [TBL] [Abstract][Full Text] [Related]
27. Pulmonary biofilm-based chronic infections and inhaled treatment strategies. Ding L; Wang J; Cai S; Smyth H; Cui Z Int J Pharm; 2021 Jul; 604():120768. PubMed ID: 34089796 [TBL] [Abstract][Full Text] [Related]
28. Pulmonary drug delivery systems for antimicrobial agents: facts and myths. Falagas ME; Michalopoulos A; Metaxas EI Int J Antimicrob Agents; 2010 Feb; 35(2):101-6. PubMed ID: 19939637 [TBL] [Abstract][Full Text] [Related]
29. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Christ-Crain M; Jaccard-Stolz D; Bingisser R; Gencay MM; Huber PR; Tamm M; Müller B Lancet; 2004 Feb; 363(9409):600-7. PubMed ID: 14987884 [TBL] [Abstract][Full Text] [Related]
33. Worldwide trends in antimicrobial resistance among common respiratory tract pathogens in children. Jacobs MR Pediatr Infect Dis J; 2003 Aug; 22(8 Suppl):S109-19. PubMed ID: 14566997 [TBL] [Abstract][Full Text] [Related]
34. Polymeric nanoparticles in development for treatment of pulmonary infectious diseases. Lim YH; Tiemann KM; Hunstad DA; Elsabahy M; Wooley KL Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2016 Nov; 8(6):842-871. PubMed ID: 27016134 [TBL] [Abstract][Full Text] [Related]
35. Local drug delivery in the urinary tract: current challenges and opportunities. Mittal R; Pan DR; Parrish JM; Huang EH; Yang Y; Patel AP; Malhotra AK; Mittal J; Chhibber S; Harjai K J Drug Target; 2018 Sep; 26(8):658-669. PubMed ID: 29251520 [TBL] [Abstract][Full Text] [Related]
36. Local administration of polymyxins into the respiratory tract for the prevention and treatment of pulmonary infections in patients without cystic fibrosis. Falagas ME; Kasiakou SK Infection; 2007 Feb; 35(1):3-10. PubMed ID: 17297582 [TBL] [Abstract][Full Text] [Related]
37. Aerosol-based efficient delivery of clarithromycin, a macrolide antimicrobial agent, to lung epithelial lining fluid and alveolar macrophages for treatment of respiratory infections. Togami K; Chono S; Morimoto K J Aerosol Med Pulm Drug Deliv; 2012 Apr; 25(2):110-5. PubMed ID: 22360316 [TBL] [Abstract][Full Text] [Related]
38. [Are new antibiotics in therapy of respiratory tract infections necessary?]. Haberl R; Wenisch C; Domej W Wien Med Wochenschr; 2003; 153(15-16):345-8. PubMed ID: 13677256 [TBL] [Abstract][Full Text] [Related]
39. Nanotargeting of Resistant Infections with a Special Emphasis on the Biofilm Landscape. Alabresm A; Chandler SL; Benicewicz BC; Decho AW Bioconjug Chem; 2021 Aug; 32(8):1411-1430. PubMed ID: 34319073 [TBL] [Abstract][Full Text] [Related]
40. Nanoantibiotics: A Novel Rational Approach to Antibiotic Resistant Infections. Engin AB; Engin A Curr Drug Metab; 2019; 20(9):720-741. PubMed ID: 31385767 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]